David Teachey Laboratory
Led by David Teachey, MD, this research program focuses on two areas: acute lymphoblastic leukemia and immune dysregulation. The first area of interest centers on the development and translation of novel therapies for acute lymphoblastic leukemia (ALL). The lab targets a number of signaling pathways in ALL and also develops and tests novel immunotherapies. The lab often uses xenograft models to study the efficacy of agents and mechanism of action of those agents directly on leukemia cells obtained from children.
Bride K, Vincent T, Smith-Whitley K, Lambert MP, Bleesing J, Seif AE, Manno CS, Casper J, Grupp SA, and Teachey DT. (2016). Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 127(1): 17-28. (Plenary Paper). PMID 26504182
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J. Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, and Grupp SA. (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery. 6(6):664-79. PMID. 27076371
Teachey DT and Pui CH. (2019) Comparative features and outcome between pediatric T- and B- acute lymphoblastic leukemia. Lancet Oncol. 20(3): e142-154. PMID: 30842058